首页> 外国专利> Pharmaceutical component and use thereof for inhibiting the genesis and metastasis of a breast cancer tumor

Pharmaceutical component and use thereof for inhibiting the genesis and metastasis of a breast cancer tumor

机译:药物成分及其在抑制乳腺癌肿瘤发生和转移中的用途

摘要

The invention relates to a pharmaceutical component and the use thereof for inhibiting the genesis and metastasis of a breast cancer tumor, wherein the pharmaceutical component is a GR agonist comprising the ATA component of Antrodia cinnamomea as the principal active component and a pharmaceutically acceptable carrier or carrier Carrier comprises micro-ribonucleic acid-708 (miR-708) is activated by transcription and activation of the glucocorticoid receptor α (GR α) so that the proliferation of breast cancer cells is inhibited and a stagnation of their cell cycle is induced by the activated component signaling activates the expression of micro-ribonucleic acid-708 (miR-708) and then inhibits the viability of NF-κB and inhibits and regulates the expression of its downstream target genes COX-2 and cMYC.
机译:本发明涉及药物成分及其在抑制乳腺癌肿瘤的发生和转移中的用途,其中所述药物成分是GR激动剂,其包含牛樟芝的ATA成分作为主要活性成分以及药学上可接受的载体或载体。包含微核糖核酸708(miR-708)的载体通过糖皮质激素受体α(GRα)的转录和激活而被激活,从而抑制了乳腺癌细胞的增殖,并通过激活而诱导了其细胞周期的停滞成分信号传导激活微核糖核酸708(miR-708)的表达,然后抑制NF-κB的活力,并抑制和调节其下游靶基因COX-2和cMYC的表达。

著录项

  • 公开/公告号DE102018120149A1

    专利类型

  • 公开/公告日2019-09-05

    原文格式PDF

  • 申请/专利权人 TAIWAN LEADER BIOTECH CORP.;

    申请/专利号DE201810120149

  • 发明设计人 CHIN-CHUNG LIN;SHENG-YANG WANG;

    申请日2018-08-17

  • 分类号A61K31/575;A61K31/568;A61K31/122;A61P35;A61P35/04;

  • 国家 DE

  • 入库时间 2022-08-21 11:44:42

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号